Compare First Solar, Inc. (FSLR) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Eli Lilly And Co — how do they compare? First Solar, Inc. trades at $179 (market cap $19.22B), while Eli Lilly And Co trades at $1,176.85 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 54.1× First Solar, Inc.'s market cap, and Eli Lilly And Co pays a 0.59% dividend while First Solar, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and Eli Lilly And Co for 93 Days on average.
| FSLR | LLY | |
|---|---|---|
Market Cap | $19.22B | $1.04T |
Volume | 2,067,793 | 3,064,878 |
Sector | Energy | Health |
52-Week High | $318.30 | $1.28K |
52-Week Low | $172.11 | $799.57 |
Typical Hold Time | 76 Days | 93 Days |
Enterprise Value | $17.69B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $178.36, down 0.98% with bearish technical signals despite strong fundamentals. The stock shows robust revenue growth from $2.6B in 2022 to $5.2B in 2025, with net income margins expanding to 32.47%. Recent patent litigation against JA Solar and increased put option activity reflect mixed sentiment. Technical indicators show resistance at $182 and support at $175, with moving averages signaling bearish momentum.
FSLR presents a value opportunity with attractive valuation ratios (P/E 11.03, P/S 3.58) and analyst consensus price target of $267.59 (50% upside). Risks include sector-wide pressure from high borrowing costs and political uncertainty. Strong cash flow generation ($2.06B operating cash flow) and consistent earnings beats support long-term growth prospects despite near-term technical weakness.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
